To debate the utility and appropriateness of real-world evidence against clinical trials for treating patients with hematologic malignancies, Chadi welcomes back Aaron Goodman, MD, hematologist, University of California San Diego, and Alan Skarbnik, MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), as well as invites first-time guest Liz Brem, MD, assistant clinical professor of hematology, UC Irvine. Can RCT designers ever escape inherent bias? Will we ever enroll a more diverse, higher volume patient population in clinical trials? Who has the right to criticize a clinical trial design? The group uses a phase I study published in Lancet Hematology to frame their arguments in this riveting, hotly contested discussion.
N/A
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
